Aortic arch

Thoracic Aortic Stent Grafts Pipeline Insights and Competitive Landscape Report 2022: Brand Positioning of Leading Companies, Application, Industry Collaborations - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 31, 2022
Health, Cardiology, Nexus, NEXUS, Heart, Sale, EVAR, Smoking, Aortic dissection, Cook Group, Bentall procedure, Growth, Competitive landscape, Patient, CVD, Vein, Medtronic, Time-invariant system, CT, Incidence, Northwell Health, Safety, Anatomy, Acquisition, Degenerative disease, Physician, Aortic arch, News, OSR, Interrupted aortic arch, Aortic aneurysm, FDA, Aneurysm, Blood, PMA, Endovascular aneurysm repair, Oil, Medical device

The "Thoracic Aortic Stent Grafts-Pipeline Insight and Competitive Landscape, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Thoracic Aortic Stent Grafts-Pipeline Insight and Competitive Landscape, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Thoracic Aortic Stent Grafts-Pipeline Insight and 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Thoracic Aortic Stent Grafts pipeline landscape.
  • This report provides a detailed study of the emerging Thoracic Aortic Stent Grafts devices along with competitive landscape to help better understand the emerging Thoracic Aortic Stent Grafts devices.
  • Thoracic Aortic Stent Grafts can be divided based on Treatment Types - Open Surgical Repair (OSR), Endovascular Aneurysm Repair (EVAR), Abdominal Aortic Aneurysm Repair, Thoracic Aortic Aneurysm Repair & Thoracic Endovascular Aneurysm Repair.

Endospan Receives FDA IDE Approval to Initiate a Pivotal Study of the NEXUS™ Aortic Arch Stent Graft System

Retrieved on: 
Monday, August 17, 2020
FDA, Health, Cardiology, Medical devices, Anatomy, Angiology, Torso, Interventional radiology, Aorta, Stent, Investigational device exemption, Aortic arch, Vascular surgery, Vascular diseases, Thoracic aortic aneurysm, Aortic aneurysm

Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease received approval from FDA of an investigational device exemption, or IDE, to start the TRIOMPHE study on the NEXUS Aortic Arch Stent Graft System (hereinafter referred to as NEXUSTM).

Key Points: 
  • Endospan , a pioneer in off-the-shelf endovascular repair of aortic arch disease received approval from FDA of an investigational device exemption, or IDE, to start the TRIOMPHE study on the NEXUS Aortic Arch Stent Graft System (hereinafter referred to as NEXUSTM).
  • The TRIOMPHE pivotal study will assess the NEXUSTM in some of the most challenging Aortic Arch Pathologies that we encounter.
  • Endospans NEXUSTM Aortic Arch Stent Graft System is the first endovascular off-the-shelf system with CE Mark to treat a greatly underserved group of patients diagnosed with a dilative lesion in, or near the aortic arch.
  • NEXUSTM Aortic Arch Stent Graft System is currently available for sale in Europe and is intended for investigational use only in the U.S.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20200817005127/en/

CryoLife Receives CE Mark for E-vita Open NEO™ Hybrid Stent Graft

Retrieved on: 
Wednesday, March 4, 2020
Medical specialties, Medicine, Angiology, Interventional radiology, Cardiac surgery, Aorta, Vascular surgery, Aortic arch, Stent, Endovascular aneurysm repair, Thoracic aortic aneurysm

ATLANTA, March 4, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-vita Open NEO, a hybrid stent graft system for the treatment of aortic arch disease.

Key Points: 
  • ATLANTA, March 4, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has received CE Mark for the E-vita Open NEO, a hybrid stent graft system for the treatment of aortic arch disease.
  • It is anticipated that the E-vita Open NEO often will be used in combination with JOTEC's thoracic stent graft offering, E-nya.
  • "We are pleased to have received CE Mark for E-vita Open NEO, our newest hybrid stent graft technology for aortic arch and descending thoracic aorta repair.
  • Arjang Ruhparwar in Essen, Germany commented, "15 years ago, the introduction of the Evita Open Plus hybrid stent graft changed conventional open aortic arch surgery.